Financial Daily from THE HINDU group of publications
Wednesday, Dec 21, 2005


Group Sites

Corporate - Announcements

Orchid's Cefprozil to hit US markets

Our Bureau

Chennai , Dec. 20

THE Chennai-based Orchid Chemicals & Pharmaceuticals Ltd will be able to tap a $117 million market in the US with launch of Cefprozil tablets (cephalosporin) after December 23, 2005, when its patent expires, according to a press release from the company.

This follows the approval of Orchid's Abbreviated New Drug Application (ANDA) by the US Food and Drug Administration (USFDA). The Cefprozil Tablets USP, 250 mg and 500 mg will be launched exclusively through Par Pharmaceuticals immediately after the expiry of the patent, the release said.

This is Orchid's eighth cephalosporin ANDA approval covering four cephalosporin products in various dosage forms. More are in the pipeline with Orchid having filed 21 ANDAs with the USFDA, the release said.

Quoting Orchid's Managing Director, Mr K. Raghavendra Rao, the release said that he was confident that Cefprozil would be a lead product in the distribution alliance with Par Pharmaceuticals in the US generics market and carve for itself a significant share in the oral cephalosporin generic formulations market in the future.

More Stories on : Announcements

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Titan plans to launch sub-Rs 300 watches

Orchid's Cefprozil to hit US markets
KCP Sugar board okays stock split
Dwarikesh Sugar begins crushing at new unit
SEBI exempts Thomas Cook from making open offer
Gas supply contract issue — NTPC files case against Reliance
Haldia Petro: TCG, Bengal Govt resolve to sort out issues
Tata BP Solar bags award
Management students' meet at Rushikonda
Diamond Hatcheries to set up feed plant near Medchal
MSD India, ICMR sign pact for studies on cervical cancer drug
NMDC in pact with Kanoria Chem, Central salt institute
GAIL, Coal India in pact for gasification projects
Natco Pharma signs pact with US co for oral drugs
NTPC likely to get seven coal blocks
Honeywell India targets $1-b revenue
BL Kashyap hopes to achieve Rs 500-cr revenues this fiscal
IBP hopeful of turnaround
B.V.R. Subbu — Openness, his forte

The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line